T-World: A highly general computational model of a human ventricular myocyte

Jakub Tomek[1,2], Xin Zhou[3], Hector Martinez-Navarro[3], Maxx Holmes[3], Thomas Bury[4], Lucas Arantes Berg[3], Marketa Tomkova[5], Emily Jo[1], Norbert Nagy[6], Ambre Bertrand[3], Alfonso Bueno-Orovio[3], Michael Colman[7], Blanca Rodriguez[3†], Donald Bers[2†], Jordi Heijman[8†]*

[1] Department of Anatomy, Physiology and Genetics (University of Oxford), [2] Department of Pharmacology (UC Davis), [3] Department of Computer Science (University of Oxford), [4] Department of Physiology (McGill University), [5] Ludwig Cancer Research (University of Oxford), [6] Department of Pharmacology and Pharmacotherapy (University of Szeged), [7] School of Biomedical Sciences (Leeds University), [8] Medical Physics and Biophysics (Medical University of Graz)

* corresponding author, jakub.tomek.mff@gmail.com

[†] joint supervision

Abstract

Cardiovascular disease is the leading cause of death, demanding new tools to improve mechanistic understanding and overcome limitations of stem cell and animal-based research. We introduce T-World, a highly general virtual model of human ventricular cardiomyocyte suitable for multiscale studies. T-World shows comprehensive agreement with human physiology, from electrical activation to contraction, and is the first to replicate all key cellular mechanisms driving life-threatening arrhythmias. Extensively validated on unseen data, it demonstrates strong predictivity across applications and scales. Using T-World we revealed a likely sex-specific arrhythmia risk in females related to restitution properties, identified arrhythmia drivers in type 2 diabetes, and describe unexpected pro-arrhythmic role of NaV1.8 in heart failure. T-World demonstrates strong performance in predicting drug-induced arrhythmia risk and opens new opportunities for predicting and explaining drug efficacy, demonstrated by unpicking effects of mexiletine in Long QT syndrome 2. T-World will be available as open-source code and an online app.

Introduction

Computational modelling and simulations of cardiac cellular and organ physiology have become an integral part of contemporary cardiovascular research, providing insights into basic physiological mechanisms[1], mechanisms of arrhythmia[1], therapy guidance[2], and drug safety assessment[3,4]. Digital evidence increasingly influences real-world applications in the pharmaceutical industry[5] and regulatory bodies such as the FDA[6] and EMA[7]. Combined with recent advances in data availability, hardware, and software, these models are driving the vision of the digital twin technology [8], producing a virtual tool that integrates clinical data acquired for an individual and that enables personalised diagnosis and treatment strategies.

Computational modelling and simulations also hold tremendous potential to contribute to reducing, replacing, and refining the use of animals in research ('3R principles'). While some animal-based studies in cardiac research are indispensable, simulations can minimise animal use by guiding experimental design, predicting outcomes, and aiding interpretation. Human-specific virtual cells can also predict functional implications of animal data in the context of human physiology, addressing critical species differences that may, e.g., make a drug safe in mice but dangerous in humans[9]. Correspondingly, the European Medicines Agency has recognised computational modelling as a key trend in advancing 3R principles[10].

Multiple successful models of human ventricular cardiomyocytes have been developed to investigate specific mechanisms of cardiac (patho)physiology and arrhythmia. Rudy-family models (ORd and ToR-ORd) excel at predicting drug responses and generating early afterdepolarisations in realistic conditions, making them valuable for drug studies comprising safety and efficacy assessment [3,4]. Bers/Grandi-family models are known for realistic calcium handling[11–13]. The Ten Tusscher 2006 (TP06) model is widely used to study arrhythmia related to restitution properties[14]. Despite their strengths, each model family lacks generality, capturing only a small subset of arrhythmic behaviours and manifesting important discrepancies with experimental data on fundamental physiology. This limits their utility for mechanistic studies, analysing multifactorial drug effects, modelling complex diseases such as Type-2 diabetes (T2D) and heart failure, or integrative arrhythmia studies. Cells and their models are highly complex and include numerous components connected through non-linear feedback loops. As a result, flaws in one model component can cascade, leading to incorrect predictions in other components and behaviors. This limits a model's predictive power and usefulness beyond its original focus. At the same time, the most innovative and relevant applications often arise precisely in these out-of-domain contexts. The lack of generality is in part also why different cellular models were typically used to study aspects of arrhythmogenesis at cellular versus organ level[1].

The absence of a comprehensive and physiologically accurate virtual cardiomyocyte impedes progress toward translational applications and expanding the context of use of cardiac simulations. To bridge this gap and unlock the full potential of cardiac simulations in research, industry, and clinic, we sought to develop a unified highly general virtual cell model. The generality should include 1) accurate recapitulation of human cellular cardiac physiology and its modulation by drugs or physiological changes, 2) the capability to manifest all key arrhythmogenic behaviours in conditions used to provoke them experimentally. This comprises early and delayed

afterdepolarisations (EADs and DADs)[15,16], alternans[17], and steep restitution of action potentials (APs)[18], 3) show suitability for multiscale modelling, enabling organ-level simulations.

Here, we present T-World, a novel virtual human cardiomyocyte that reproduces for the first time all key cellular arrhythmic mechanisms and shows comprehensive agreement with data on human cardiac physiology. Comparison to data not used in model creation demonstrates robust predictive accuracy at a broad range of tasks. T-World integrates electrophysiology, calcium handling, cardiomyocyte contraction, sympathetic stimulation, and sex differences, enabling comprehensive studies of their interactions. T-World is freely available via Matlab, CellML, C, and CUDA, with a free-to-use online graphical interface for non-coders (also runnable in Python). This model advances our understanding of cardiac electrophysiology and arrhythmogenesis by 1) identifying a likely sex-specific arrhythmia risk in females linked to restitution properties, 2) showing applicability to analysis of drug efficacy through analysis of mechanism of action of anti-arrhythmic drugs, and showing excellent performance in drug safety testing and, 3) identifying causes of high arrhythmia risk in T2D, and 4) suggesting NaV1.8 as a relevant treatment target in heart failure.

Methods

T-World is a virtual cell model using sets of ordinary differential equations to describe, based on experimental data, the dynamics of ionic currents, fluxes, and subcellular signalling. The overall cell architecture and calcium handling were mainly inspired by the Bers/Grandi family of models[11–13], with most ionic current formulations being inspired by the ToR-ORd model[4]. In order to enable all key arrhythmic behaviours in relevant conditions, and to avoid limitations of these frameworks with regards to basic physiological behaviours and response to (patho)physiological changes, we introduced numerous innovations, such as a new hybrid approach to coupling L-type calcium current and ryanodine receptors, new L-type calcium current model, heavily revised model of the ryanodine receptor, re-developed model of sodium-potassium pump, and a wide array of changes to most cell components. The 'World' in the model's name reflects the fact that model designs and expertise from the whole world were essential in its creation, and it goes beyond outputs of a single group.

Please see **Supplementary Methods** for a detailed description of the following:

1. Model architecture
2. Calibration and validation criteria for T-World development and evaluation
3. Description of equations describing the ionic currents and fluxes
4. Contractility representation
5. CaMKII and β-adrenergic signalling
6. Sex differences
7. Organ-level simulation methodology
8. Methodology for studies on arrhythmogenic behaviours.
9. Methodology for sample applications: in silico trials, type 2 modelling, and NaV1.8 current investigation
10. Graphical user interface
11. Notes on implementation

12. Sources of implementation of other models

T-World is distributed as open-source code and is available at **<will-be-provided-upon-acceptance>**, including sample scripts demonstrating its functionality. An online graphical user interface enabling running T-World simulations is available at **<will-be-provided-upon-acceptance>**. Background of the T-World development, including the description of various dead ends that we encountered during development, will be provided at the blog underlid.blogspot.com**.**

Results

Representation and validation of cell and organ physiology



Figure 1. Cell and organ physiology. A) *Conceptual diagram of the T-World model and its potential applications. See Methods for a detailed diagram including all ionic currents and cellular compartments.* ***B)*** *Endocardial action potential of*

T-World versus experimental ranges [19]. Slightly higher peak in simulation versus data was chosen, given that our model is a single cell, whereas the experimental data are in small tissue samples which show a reduced peak due to cell-to-cell coupling. ***C)*** *Calcium transient (CaT) of T-World with highlighted biomarkers versus experimental ranges for: CaT duration at 90% recovery level (CaTD90, shown in green), time to peak (ttp, shown in yellow), and calcium transient amplitude (max, shown in red), based on standard error of mean ranges data by Coppini et al.[20]* ***D)*** *Active tension developed by T-World with highlighted biomarkers versus experimental ranges for: time from peak to 95% recovery (rt95, shown in green), time to peak (ttp, shown in yellow), and maximum active tension (max, shown in red), based on Margara et al.[21].* ***E)*** *Independent validation of the APD prolongation or shortening induced by 1 μM E-4031 (70% I_{Kr} block), 1 μM HMR-1556 (90% I_{Ks} block), 1 μM nisoldipine (90% I_{CaL} block), and 10 μM mexiletine (54% I_{NaL}, 9% I_{Kr}, 20% I_{CaL} block) at 0.5, 1.0 and 2.0 Hz pacing in the four models. Drug concentrations and their effects on channel blocks are based on O'Hara et al.[19] Please note the distinct y-axes for the four drugs.* ***F)*** *Healthy ventricular model constructed from clinical MRI data and ECG simulation (solid line) compared with the ECG record from the patient used for the ventricular anatomy.* ***G)*** *Ventricular fibrillation simulation in the setting of acute ischemia, when stimulation rate is progressively increased. Heart snapshots above the ECG illustrate different stages of progression towards fibrillation.*

Based on extensive experimental data, the T-World model represents a broad range of ionic currents and fluxes across distinct cellular compartments, as well as subcellular signalling pathways and contractility (see **Figure 1A** for a high-level overview). Distinct model components are described by sets of ordinary differential equations, constructed to recapitulate baseline experimental data on single ionic currents and other cellular elements. Coupling all those components together yields a virtual cardiomyocyte with a high degree of biological detail and realism, which can be used as a model system in cardiac research.

The three key outputs of a cardiomyocyte model are its AP, calcium transient (CaT), and the resulting active tension during contraction. T-World shows a very strong agreement with human AP data[19] with regards to AP duration (APD), resting membrane potential, and the overall shape of the AP during plateau and recovery (**Figure 1B**). It is in better agreement with human AP shape than most prior state-of-the-art models (**Supplementary Note 1**). The CaT is also in excellent agreement with human data on time to peak, duration, and amplitude[20] (**Figure 1C**). T-World incorporates the Land model of contraction[22] as in the work of Margara et al.[21], and its outputs are fully consistent with experimental data on time to peak force, amplitude, and time to 95% recovery of contractility in human myocardium[21] (**Figure 1D**).

The cardiac AP is determined by the specific mixture of ionic currents, and a given AP shape can be achieved through various combinations and balances of currents[23]. To verify that the balance of key ionic currents in T-World is human-like, we validated it by simulating its exposure to four simulated channel-blocking drugs at three pacing rates (**Figure 1E-H**). The strong predictive performance predisposes T-World to applications in safety pharmacology. See **Supplementary note 2** for comparison to other models (noting, in particular, problematic performance of TP06).

Excitation-contraction coupling (ECC) in cardiomyocytes is a process that ensures that electrical signals translate into muscle contraction and pumping of the heart. It involves 1) electrical activation of the cell, 2) consequent opening of L-type calcium channels, 3) triggering intracellular calcium release from the sarcoplasmic reticulum (SR), 4) binding of the released calcium to the contractile apparatus and resulting physical contraction. To correctly represent ECC, we introduced numerous new developments in T-World compared to prior models, yielding a virtual cell that is in excellent agreement with available data, while being mechanistically realistic. See **Supplementary note 3** for details of ECC development and validation. Briefly, the model maintains the realism of calcium handling from Bers/Grandi formulations, while improving upon several important

limitations of the framework. First, the model shows more physiological timing of calcium release in response to L-type calcium channel opening with implications for better AP shape and overall model plausibility. Second, T-World correctly responds to changes in SERCA pump function, which enables plausible representation of disease and sympathetic nervous activity. The model shows comprehensive agreement with heart-rate-dependence of various components of ECC, such as calcium transient amplitude, contraction force, or SR calcium content; something not achieved in prior models. Sodium concentration rate-dependence is also captured well, as is the relative contribution of SERCA, NCX, and sarcolemmal calcium pump to clearance of calcium from cytosol within an AP. Finally, T-World has human-like properties of the L-type calcium current (essential in ECC), including current-voltage relationship, recovery from refractoriness, and relative contribution of voltage- and calcium-dependent inactivation.

ECC and electrophysiology are strongly modulated by the β-adrenergic (βAR) signalling pathway, which mediates the myocardial response to sympathetic nervous stimulation. Our model includes the Heijman et al.[24] βAR description, with modifications to account for updates to ionic currents and inclusion of the contractile apparatus in the model (see **Supplementary Methods**). The integrated model was calibrated based on human AP data, with subsequent validation demonstrating a correct effect on CaT and contraction dynamics (**Supplementary Note 4**).

Pronounced differences exist between hearts from females and males, which subsequently translate into differential risk of various adverse cardiac outcomes[25]. Given the extent and importance of sex differences in cardiovascular physiology, we constructed a male and a female version of T-World, based on available experimental data and prior simulation approaches[26–28], showing correctly longer APD and slightly reduced CaT amplitude and contraction in female myocytes (**Supplementary Note 5**), supporting the utility of T-World for studies on sex differences in cardiac (patho)physiology. There are also T-World versions for endocardial, midmyocardial, and epicardial myocytes.

The virtual cell model can be used to build a virtual organ based on clinical MRI data, which enables organ-level studies and reconstruction of ECG. We assessed the model's performance across scales by building a 3D model based on a patient's anatomy, with the simulation yielding a human-like ECG signal (**Figure 1F**) [29,30]. A major application of whole-organ models is the study of arrhythmia such as ventricular fibrillation (VF), where the impact of tissue-level phenomena such as fibrosis and conduction heterogeneities can be considered. However, numerous advanced models like ToR-ORd or ORd struggled to produce VF dynamics unless their parameters were specifically tuned for this purpose (in addition to imposing a pro-arrhythmic substrate such as localised ischemia)[30,31]. Importantly, T-World does reproduce VF, as shown in **Figure 1G**, where VF appears in the setting of acute anteroseptal ischemia and progressively increasing rate of stimulation. Initially, the electrical propagation is stable, only manifesting ST segment elevation (a hallmark of acute ischemia), but as the stimulation rate is increased, re-entrant wavefronts appear (**Figure 1G**, snapshots 2,3), and gradually progress to spiral wave breakup and VF (snapshot 4).

Cellular arrhythmic behaviours in T-World



Figure 2. EADs, DADs, and alternans in T-World. A) *Experimental data showing EADs at 0.25 Hz pacing, with 85% block of I_{Kr} with dofetilide[32]. **B)** EADs evoked in T-World under corresponding conditions. **C)** Demonstration of differential EAD formation under varying degrees of I_{Kr} availability in the following types of myocytes: male, female, and female + increased I_{CaL}, reflecting the basal part of the heart in a rabbit study[33]. The y-axis shows action potential duration for a range of I_{Kr} scaling factors (fraction of current versus baseline) on the x-axis, with sharp transitions corresponding to changes in the number of EADs. Insets show APs at corresponding dashed lines. **D)** Examples of triggered activity resulting from DADs. The end of the pre-pacing train is shown in blue, with the spontaneous activity given in red. **E)** Illustration of concurrent oscillations in CaT and APD. LL = large/long CaT and APD respectively, SS = small/short. **F)** Modulation of calcium alternans by reduced and increased SERCA activity, as well as by βAR stimulation.*

Early afterdepolarisations

EADs, extrasystolic depolarisations during an AP, contribute to arrhythmogenesis and are commonly linked to drug-induced cardiotoxicity and long QT syndromes, being typically driven by the reactivation of $I_{Ca,L}$ during prolonged APD[15] (**Figure 2A**). T-World replicates EADs under realistic conditions of drug-induced long QT (**Figure 2B**), similar to ToR-ORd and ORd models[4,19], with a 13-mV amplitude, similar to experimental observations[32]. In contrast, the TP06 model requires nearly tripled I_{CaL} to manifest EADs[34], likely due to excessive I_{Ks} providing strong repolarisation reserve. The Morotti2021 model[13] (the most recent human model from the Bers/Grandi family) similarly necessitates a +150% I_{CaL} increase to induce EADs (**Supplementary Figure S23**).

T-World also highlights sex differences in EAD vulnerability. The female T-World variant requires less I_{Kr} inhibition to induce EADs compared to the male variant, indicating greater EAD vulnerability (**Figure 2C**), supporting data showing higher risk of drug-induced arrhythmia in female hearts[27,35].

Additionally, female-specific apicobasal I_{CaL} gradients linked to estrogen[36] suggest an additional risk of EADs in basal regions of the heart in female models. Spatially constrained EADs resulting from such gradients are likely to increase dispersion of repolarisation and may promote arrhythmogenesis at the tissue level beyond the EAD risk itself [37].

Delayed afterdepolarisations

DADs are arrhythmia triggers occurring during diastole. They result from spontaneous SR calcium release, generating inward currents (primarily via NCX) that depolarise the cell[38], and are particularly prominent in diseased hearts, such as in heart failure[39]. DADs arise from stochastic subcellular calcium sparks best simulated by models with spatial calcium handling and stochastic gating[40]. However, given the high computational cost of such models, 'common pool' models with similar complexity as T-World are often used to emulate DAD generation efficiently, especially Bers/Grandi-like models such as Morotti2021[11,13]. By contrast, ToR-ORd cannot produce any DADs due to its RyR activation mechanism, while TP06 can yield DADs following parametric changes, but these differ substantially from experimental recordings[41].

T-World manifests spontaneous calcium releases and DADs (**Figure 2D**), and it can generate DAD trains, as observed in certain experiments[42] (**Supplementary Figure S24**). Spontaneous releases are terminated when the SR content becomes sufficiently low following the spontaneous releases, similar to experimental parallel measurements of intracellular and SR calcium[43]. In this regard, our model differs from Morotti2021, where DADs stop occurring even when SR calcium keeps increasing (**Supplementary Figure S25**).

To validate DADs in the model, we confirmed that faster pre-pacing and RyR sensitisation promote DADs in T-World, as seen experimentally (**Supplementary Figure S26**). Furthermore, for applications requiring stochasticity of DADs, we developed a version of T-World that includes stochastic store-overload-dependent RyR release akin to the method by Colman et al.[44] (**Supplementary Figure S27**).

Calcium and action potential alternans

Cardiac alternans, a periodic oscillation between long and short APDs, creates a pro-arrhythmic substrate, promoting conduction block [45] and increasing arrhythmia risk[46]. APD alternans is typically driven by underlying CaT oscillations and occurs at rapid heart rates[47]. While common at high pacing rates in living hearts, many computer models do not recapitulate it, including the Bers/Grandi family on which most of T-World calcium handling is originally based.

Thanks to its improved calcium handling, T-World produces AP and CaT alternans at realistic frequencies[48], with mild alternans at 260 ms and pronounced alternans at 240–250 ms (**Figure 2E, Supplementary Figure S28**). Alternans is electromechanically concordant (long APD corresponds to large CaT), matching experimental data in human-relevant species[49–51]. T-World shows CaT alternans even when a fixed AP shape is imposed, confirming calcium oscillations as the primary driver (**Supplementary Figure S29**).

A major improvement of T-World compared to prior state of the art is its correct response of alternans to SERCA pump changes. Conditions like heart failure or pharmacological or transcriptional SERCA reduction increase alternans vulnerability[52–54], with alternans appearing at

slower pacing rates. T-World accurately reflects this by showing alternans at slower rates with SERCA reduction (**Figure 2F**). This is in contrast with ToR-ORd, where SERCA inhibition suppresses alternans (**Supplementary Figure S30**). Finally, we validated T-World by showing that an increase in SERCA function or βAR activation suppress alternans (**Figure 2F**), in line with experimental data[55,56].

Steep S1-S2 restitution

Steep APD restitution promotes arrhythmias by facilitating reentry and spiral wave breakup in cardiac tissue[14,57]. It is measured using an S1-S2 protocol, where a premature stimulus (termed S2) follows a train of stimuli (termed S1), generating a curve relating APD to the preceding diastolic interval (**Figure 3A**). Slopes of the restitution curve greater than 1 facilitate proarrhythmia, and human studies show that maximum curve slopes slightly above 1 are not uncommon [58,59]. The TP06 model has been historically popular, because of its steep restitution properties. At the same time, e.g. the ToR-ORd model, on which most of T-World's electrophysiology is based, has a relatively flat restitution (peak slope ~0.5), limiting its utility in these aspects. However, our revised L-type calcium current and other developments lead T-World to exhibit good agreement with experimental restitution data (**Figure 3A**) and S1S2 slope >1 in a part of the curve for S1 interval of 1000 ms (**Figure 3B**). The importance of steep restitution is supported by the fact that T-World can reproduce VF (**Figure 1G**), unlike the prior ToR-ORd model, which required substantial adaptations to achieve VF.

In 2017, Shattock et al.[18] showed that the maximum slope of the restitution curve is largely determined by the steady-state APD of a cell. Specifically, the longer the APD, the steeper the restitution (**Figure 3C**), which was corroborated by multiple studies using different means of changing APD [60–62]. Importantly, T-World is the only model among those capable of steep restitution that recapitulates this feature (**Figure 3D**), with the TP06 model showing a weakly inverse APD-slope relationship, and the Morotti2021 a strongly inverse one (**Supplementary Figure S31**). This makes T-World uniquely suitable for studying how APD changes due to disease or drugs modulate arrhythmic risk via restitution changes.

One notable exception to the observation by Shattock et al. is the effect of βAR stimulation, which shortens APD, but steepens the S1S2 slope in humans[58]. As an independent validation, we simulated the effect of βAR activation in the T-World model, which correctly predicted the phenotype (**Supplementary Figure S32**). Furthermore, we validated that shortening of the S1 interval correctly flattens the S1S2 restitution (**Supplementary Figure S33**).

Measuring restitution slope separately for the male and female versions of T-World, we observed a steeper slope in the female myocyte (**Figure 3E, Supplementary Figure S34**). This would point to an increased risk of arrhythmia in female hearts through steeper restitution, but intriguingly, we were unable to find any experimental study addressing this hypothesis. However, we were able to obtain human ventricular data from the study by Lovas et al. [63] and re-analysed them for sex differences in peak slope. Mean (SD) peak slope in males was 1.54 (±0.63), increasing to a mean of 2.38 (±0.92) in females (p=0.069, t-test) (**Figure 3F**). This suggests that females may have steeper restitution properties, a previously underappreciated sex-specific hazard.



Figure 3. S1-S2 restitution and stability of arrhythmic behaviours. A) *S1-S2 restitution curve in the T-World, ToR-ORd, Morotti2021, and TP06 models, and a range of human studies [58,63–65]. **B)** Comparison of S1-S2 restitution slopes across T-World, ToR-ORd, Morotti2021, and TP06 models. **C)** Positive relationship between APD of a cell and its peak S1-S2 restitution slope, observed experimentally [18]. **D)** Corresponding simulation in T-World showing that when a range of ion channel conductances are varied (see Methods for details), cells with longer APD generally show a steeper slope of restitution. **E)** Steepening of restitution in female versus male myocytes in baseline T-World. **F)** Experimental human data comparing peak restitution slope in males vs females (N=7 in both groups, p-value obtained using unpaired t-test).*

Stability of arrhythmic behaviours

To validate generality and robustness of T-World, we investigated the stability of the cellular arrhythmic behaviours under parameter perturbation using a population-of-models approach. While it is natural for cells, living and simulated alike, to manifest arrhythmogenic behaviours at slightly different conditions, the majority of cells should be fundamentally capable of manifesting them. In **Supplementary Note 6**, we demonstrate that T-World is highly robust with regards to its arrhythmia precursor capabilities, which are its intrinsic properties, rather than phenomena that only occur for highly specific sets of distinct parameters for each property.

Using T-World to predict drug effects and elucidate arrhythmia mechanisms in disease

The robust representation of many cellular arrhythmia mechanisms makes T-World highly suitable to facilitate a better understanding of their role in (patho)physiological conditions. Here, we show how T-World can advance assessment of drug effects and provide insight into arrhythmogenic mechanisms in diseases that may include diabetes, heart failure, or monogenic arrhythmia disorders (e.g., the Long QT syndrome).

Drug safety and efficacy assessment

Prediction of drug safety through in silico trials is a successful translational application of mechanistic computer models, with considerable uptake by industry and regulators [3]. This is crucial as cardiac side effects are a major cause of drug attrition and market withdrawal [66]. To demonstrate utility of T-World for drug safety, we conducted an in silico trial using populations-of-models [3,4], comparing predictions against clinical risk data for 61 drugs (**Figure 4A**). Compared to prior works, we updated drug safety annotation based on the most recent version of the Crediblemeds classification [67], and pharmacological data for several compounds (see Methods).

A population of 343 models, constrained by experimentally informed human reference ranges for APD, CaT, and contraction biomarkers (**Supplementary Figure S35**) was exposed to 61 drugs at doses up to 100 times therapeutic levels. The model correctly predicted all no-risk drugs as safe and all high-risk drugs as unsafe. Classifying the drugs into two categories of safe (*no risk*) and unsafe (*high*, *possible*, or *conditional* risk) yielded a prediction accuracy of 87%, with 79% sensitivity and 100% specificity (**Figure 4B**). This represents an improvement over the prior ToR-ORd model, highlighting the robustness of T-World despite its entirely different calcium-handling system and revised ion current formulations.

A drug effect prediction can be reliable only when the underlying drug description data are accurate. T-World can identify incorrect pharmacological descriptions of drugs, which can limit prediction accuracy. When a drug with known phenotypic effect (e.g. changes to APD or contractility) is simulated, a discrepancy between the simulation and known reality indicates that an important effect of the drug is not included in the drug description data. We illustrate this using lidocaine, a safe sodium-channel blocker, where one of two available descriptions was excluded a priori during data curation. Both versions block peak I_{Na} and weakly block I_{Kr}, with one additionally potently blocking I_{NaL}. Lidocaine is known to shorten APD[68] , and this is recapitulated only by the version including the I_{NaL} block, indicating its superiority (**Figure 4C,D**). Interestingly, the incorrect description generates EADs and falsely indicated arrhythmic risk (**Figure 4C,D**), highlighting the need to exclude incomplete drug descriptions. In this case, exclusion of the non-I_{NaL} formulation is independently supported by studies directly demonstrating I_{NaL} inhibition by lidocaine[68].

Similarly, we also identified an inaccuracy in the description of cilostazol, with the original drug description failing to predict the effect of the drug on contractility. This resulted from its arguably main effect of PDE3 inhibition not being included in the pharmacological data, which focused on ion channel blockade only (**Supplementary Figure S36**).

Finally, T-World can be used for studies on drug efficacy, either by identifying promising combinations of single channel blocks, or by disentangling different pro- and anti-arrhythmic effects of drugs with complex multi-channel profiles. Recently, the multichannel blocker mexiletine was proposed against Long QT syndrome 2 (LQTS2) [69] caused by APD prolongation due to loss-of-function mutations in I_{Kr}. In **Supplementary Note 7**, we unpick the positive effect of mexiletine in a LQTS2 version of T-World, linking it to dual inhibitory effect of the drug on I_{NaL} and I_{CaL}, which outweigh its I_{Kr}-blocking effect. Further research is required to assess whether the drug blocks I_{Ks}, which could be problematic during βAR activity.



Figure 4 In silico drug safety and efficacy assessment. A) *Schematic of the in silico drug trial procedure, showing how pharmacological data on dose-dependent inhibition of various currents by cardioactive drugs are applied to calibrated populations of models. Subsequently, arrhythmogenic behaviours are detected, scored, and the prediction can be compared to reference clinical risk.* ***B)*** *Predicted risk scores for 61 drugs with, with color-coded clinical risk, as in [3,70]. Tables of true/false classifications are provided in the right part for T-World and ToR-ORd. Please see Methods for a summary of how several data updates lead to a subtly different performance of ToR-ORd in our study compared to the original publication[4].* ***C)*** *Effect of the first lidocaine description (with I_{NaL} effect) on AP to the left, showing overall safety to the right (no model in the model manifests an EAD).* ***D)*** *Similar plot for the second lidocaine description available in the database, showing gradual dose-dependent APD prolongation to the left and repolarisation abnormalities to the right. In C, D, lidocaine effect is shown at the maximum concentration of 100x.*

Assessing arrhythmogenesis in type-2 diabetes

The generality of T-World enables the creation of predictive disease-specific models. T2D is a major 21st-century epidemic linked to increased mortality, with cardiovascular disease as the leading cause of death. Sudden cardiac death from ventricular arrhythmia is the primary driver, yet the mechanisms behind ventricular arrhythmogenesis in T2D remain poorly understood [71]. Limited human data on ionic currents and calcium-handling proteins [72] show only partial alignment with

heterogeneous animal studies. Progressive cardiac remodelling in T2D further complicates consistent disease characterisation.

A significant portion of sudden cardiac deaths in T2D occur in patients using potentially proarrhythmic drugs[71]. This suggests hidden cardiotoxicity in T2D, with usually safe drugs (or safe drug concentrations) becoming dangerous. To investigate this, we created a range of models (D1-D6) reflecting key T2D phenotypes from literature, primarily using human data supplemented by animal studies (**Supplementary Methods – T-World applications**). All models exhibited AP prolongation (**Figure 5A**), consistent with clinical QT prolongation in T2D [73–75]. All diabetic model variants are more vulnerable to EADs (**Figure 5B)**, requiring less I_{Kr} inhibition to trigger EADs. This includes those with reduced I_{CaL} (D3-D6), which could be thought to be more protected. Key drivers of EAD risk were I_{Kr} reduction and I_{NaCa} increase, further heightened by CaMKII hyperactivity and increased I_{CaL} in D1-D2 (**Figure 5C**). I_{CaL} reduction alone (a component of D3-D6) showed reduced risk but not enough to offset other remodelling effects. This suggests that across different formulations of T2D remodelling, T2D patients require less I_{Kr} inhibition to manifest EADs, therefore facing higher arrhythmia risk at drug doses considered safe for non-diabetic individuals.

A different arrhythmogenic behaviour that is markedly increased in T2D patients is alternans[76]. We used the D1 version of T-World, which has recapitulated the clinical observation, showing alternans at slower pacing compared to non-diabetic versions (**Figure 5D**). Interestingly, Bonapace et al. furthermore observed that alternans vulnerability is positively associated with and diastolic dysfunction in T2D patients[77]. To investigate this phenomenon in T-World, we correlated the slowest pacing rate for CaT alternans with diastolic function (tau of relaxation) in a population of models with perturbed parameters. Models prone to alternans exhibited impaired relaxation, consistent with clinical data (**Figure 5E**). We hypothesised and subsequently confirmed that reduced SERCA pump function, crucial for relaxation and calcium clearance, can causally drive this relationship (**Supplementary Note 8**).

$Na_V1.8$ can drive EADs in the failing heart

Cardiac disease may remodel ionic currents active under physiological conditions, but it can also involve expression of nonstandard ionic currents, absent in a healthy heart. We employed T-World to investigate the role of $Na_V1.8$, a primarily neuronal sodium channel subtype with recently much debated functionality in the heart. While $Na_V1.8$ is minimally expressed in healthy hearts[78], it appears in hypertrophic or failing hearts, and may contribute disproportionately to the late sodium current I_{NaL}[79,80]. Increased I_{NaL} can in general promote arrhythmias by prolonging APD (leading to EADs) or increasing sodium influx, reducing NCX calcium efflux and causing DADs. However, given $Na_V1.8$'s unique biophysical properties, including right-shifted activation and inactivation compared to $Na_V1.5$ (**Supplementary Figure S37**), we hypothesised it could directly generate EADs by providing depolarising current during the late AP plateau.



Figure 5. Arrhythmogenesis promotion by Type 2 diabetes and $Na_V1.8$ current. A) *Comparison of APs of six distinct formulations of T2D remodelling (see Methods for details.* ***B)*** *Action potentials of control and T2D models across a range of I_{Kr} multipliers (on y-axis). Sharp transitions between colours indicate a change in the presence of an EAD. Specifically, the lowest teal point on the y-axis (APD of ca. 900) indicates the highest I_{Kr} availability which supports EAD formation.* ***C)*** *The same type of visualisation showing how single elements of T2D remodelling considered throughout D1-D6 models, added to the control model, alter EAD vulnerability. The '+CaMKII' column also involves an increase in I_{NaL}, as described in Methods, and '-I_{CaL}' corresponds to 80% I_{CaL} density compared to control model.* ***D)*** *Comparing alternans vulnerability (slowest pacing rate which induces CaT alternans) between population of control vs T2D models. The calibrated population of 796 models used in Results: Stability of arrhythmic behaviours was used as the control population, with T2D models created by adding diabetic remodelling to each of those models.* ***E)*** *A scatterplot of tau of mechanical relaxation versus alternans threshold in the simulated T2D population* ***F)*** *Comparing control T-World model AP to APs obtained when two different amounts of NaV1.8 current are added (expressed as relative percentage of peak I_{Na}).*

Introducing a small $Na_V1.8$ current (~0.3% of peak I_{Na}) to T-World prolonged APD (**Figure 5F**), consistent with its role as an I_{NaL} source. Strikingly, increasing $Na_V1.8$ by 2.75-fold (to only 0.8% of peak I_{Na}) triggered EADs at 1 Hz pacing (**Figure 5F**). These EADs emerged at a take-off potential of -30 mV, clearly distinct from I_{CaL}-driven EADs at -13 mV (**Figure 4B**). Simultaneous tracking of $Na_V1.8$ current and I_{CaL} during EADs revealed that $Na_V1.8$ initiates depolarisation, subsequently activating I_{CaL} in a dual-current process (**Supplementary Figure S38**). Therefore, $Na_V1.8$ can directly trigger EADs rather than merely prolong APD to facilitate I_{CaL} reactivation, potentially co-explaining elevated arrhythmic risk in those patients[81]. This mechanism suggests $Na_V1.8$ as a possible anti-arrhythmic target, e.g., providing additional rationale for the use of ranolazine, which is protective in the hypertrophied heart[20,82], and which blocks $Na_V1.8$[83]. Future work on $Na_V1.8$ modelling is suggested in **Supplementary Note 9**.

Discussion

Here, we present the development, calibration, validation, and application of T-World, a novel computer model of the human ventricular cardiomyocyte. This model addresses a longstanding but

unresolved need for a highly general virtual cardiac cell model with robust baseline physiology, capable of replicating all key cellular mechanisms of arrhythmia. The model utilises a range of new developments, as well as components and ideas from two influential modelling families from the Rudy[4,19] and Grandi and Bers labs[11,12]. It is the first model to unify those two different approaches to modelling cardiac cells, improving upon their strengths, while resolving their known limitations. In addition to good representation of DADs stemming from the Bers/Grandi framework[11,12] and presence of EAD in relevant conditions such as in ToR-ORd[4], the model now manifests data-like restitution properties and calcium-driven alternans which correctly responds to changes in SERCA pumps. The model gains credibility through rigorous independent validation on unseen data, its construction from well-characterised components, and its human-specific design, which bypasses the species differences inherent to animal experiments (elaborated in **Supplementary Note 10**). Its universality, predictivity, and adaptability make it an excellent tool for basic cardiac research at cellular and organ level, pharmaceutical applications, and development of patient virtual twins [8].

T-World presents an important step towards realising the vision of the 3Rs: reduction, refinement, and (partial) replacement of animal use in research and industry. It can also work synergistically with *in vitro* models such as induced pluripotent stem cell-derived cardiomyocytes, helping interpret their so far still typically immature phenotype in the context of the adult heart[84]. T-World's human nature can also be leveraged to utilize animal-based measurements (such as protein level changes) and predict their functional implications for the human heart, thereby "humanising" the data.

The fact that T-World directly represents cellular biology means that it can be used to investigate the modulation of its components by drugs and/or disease-related alterations. It can be for example used to understand mechanisms of high arrhythmia risk in a given disease, and then help discover drugs that can ameliorate such a risk. We used T-World to disentangle mexiletine's antiarrhythmic effects in Long QT syndrome type 2, showing it results from a dual I_{NaL} and I_{CaL} blockade. Such insights may be also used in future to explore new therapeutic combinations of distinct drugs. T-World is furthermore suitable for carrying drug arrhythmia studies in a sex-specific manner, having reproduced the higher risk of drug-induced arrhythmia in females [27,35]. Finally, with its representation of contractility and improved excitation-contraction coupling, T-World is well-suited for studying drug effects on contractility. This is another rapidly developing domain of applications with high relevance for industry[85]. An advantage of the comprehensive nature of T-World over single-purpose predictors is that it can be used to address compound queries, such as "find the most anti-arrhythmic drug for a given condition without compromising contractility".

T-World will be useful in preclinical drug safety testing, one of the most established translational applications of non-animal methods, with significant industry adoption. We demonstrate T-World's excellent performance in drug safety testing through population-of-models in silico trials, slightly surpassing the prior state-of-the-art ToR-ORd[4]. We believe that the main barrier to improved drug safety prediction now lies in data quality rather than model quality, as shown by our data curation process. Notably, we introduce a novel use of simulations to identify inaccuracies or missing data in drug action datasets, based on the capability of the drug description data to reconstruct known phenotype. Discrepancies between simulated and observed drug effects on e.g., action potential or contractility can signal missing mechanisms in drug data description, guiding additional

measurements. Missing effects likely contribute to misclassification of several drugs in our study (**Supplementary Note 11**).

Notably, while the drug-induced arrhythmia risk mostly results from EADs, our study indicates via simulations and subsequently analysed human data that females are also at a higher risk of a steep restitution slope, which may promote arrhythmia at the tissue level[14,57]. This finding highlights how simulations can be used to drive discovery in biological data. However, given the small sample size and exploratory nature of the data, further larger-scale studies are needed. Considering the elevated risk of EADs and steep restitution in females, our study reinforces the urgency of sex-specific drug dosing and treatment guidelines, which is currently not sufficiently addressed[86].

Arrhythmias pose a significant risk in heart disease, and T-World's improved baseline physiology and arrhythmic behaviour make it ideal for studying complex cardiac diseases. Using T-World, we constructed a pilot cell model for Type 2 diabetes (T2D), a condition with high arrhythmic burden but limited mechanistic understanding[71]. The model revealed increased risks of EADs and alternans, with T2D patients facing heightened vulnerability to drug-induced arrhythmia, which can explain elevated rates of sudden cardiac death in this population. The suggested strong involvement of NCX in the elevated EAD risk may warrant investigation of therapeutic potential of NCX blockers such as ORM-10962, which inhibit both NCX and I_{CaL} (both pro-EAD factors) while not compromising contractility [87]. At the same time, ORM-10962 was shown to inhibit alternans experimentally[88], possibly targeting also the second pro-arrhythmic aspect in T2D. Despite promising results achieved, we note the urgent need to collect new, high-quality human datasets to characterise and understand how T2D dysregulates the heart, given the paucity of existing data.

T-World's realistic calcium handling and ECC make it well-suited for diseases with significant calcium remodelling, such as heart and post-infarction remodelling. Unlike models like ToR-ORd, T-World can produce DADs, important in such diseases [39]. A particular strength pertaining to arrhythmia mechanisms is that T-World exhibits increased alternans vulnerability with reduction in SERCA pumps, both hallmarks of those diseases [52,53]. This is an improvement over major prior human models such as Grandi et al. [12] which lacked alternans, or ORd and ToR-ORd[4,19], which do not respond well to SERCA changes.

T-World can be applied to study the role of nonstandard channels absent in healthy hearts, but present in disease. In our study, we show and explain how the "brain-type" $Na_V1.8$ channel may directly contribute to arrhythmia in the diseased heart through its unusual gating properties. Our results indicate $Na_V1.8$ as a potential important target in heart failure.

The inclusion of βAR signalling and excitation-contraction coupling modulation makes T-World highly suitable for exploring the neurocardiac axis in arrhythmia and sympathetic nervous system studies[89]. It is particularly well applicable for studies on arrhythmia and sympathetic nervous system, given that the validation has demonstrated strong predictive performance with regards to modulation of multiple arrhythmic mechanisms by sympathetic nervous activity.

Several limitations of T-World, most of which are intrinsic to the level of detail modelled, are given in **Supplementary Note 12.**

The universality of T-World and its open-source nature predisposes it to the development of derived cell models and their integration in organ-scale models. This includes other excitable cells (e.g., atrial, sinoatrial, Purkinje, or neuronal), inclusion or adaptation of ionic currents, and addition of new signalling pathways. To expand the model generality, we anticipate it will be particularly important to represent dynamic regulation of trafficking and transcription [90] enabling studies on long-term remodelling, representation of metabolism and reactive oxygen species[91], and integration with AI-driven structural modelling[92].

Acknowledgments

J Tomek is supported by the Sir Henry Wellcome Fellowship (222781/Z/21/Z). J Heijman was supported by the Netherlands Heart Foundation (grant no. 01-002-2022-0118, EmbRACE: Electro-Molecular Basis and theRapeutic management of Atrial Cardiomyopathy, fibrillation and associated) and the Netherlands Organization for Scientific Research (NWO/ZonMW Vidi 09150171910029). D Bers is supported by NIH grants P01-HL141084 and R01-HL092097. This work was also supported by a Wellcome Trust Fellowship in Basic Biomedical Sciences to B Rodriguez (214290/Z/18/Z) and the CompBioMedX project (to B Rodriguez., EP/X019446/1). This study used high-performance computing resources from the Polaris supercomputer at the Argonne Leadership Computing Facility (ALCF), Argonne National Laboratory, United States of America. The US Department of Energy's (DOE) Innovative and Novel Computational Impact on Theory and Experiment (INCITE) Program awarded access to Polaris. The ACLF is supported by the Office of Science of the US DOE under Contract No. DE-AC02-06CH11357. The project was further supported by the National Research Development and Innovation Office (NKFIH FK-142949 for N Nagy). TM Bury is supported by a Fonds de Recherche du Québec - Nature et technologies (FRQNT) postdoctoral fellowship. A Bueno-Orovio acknowledges support from the Innovate UK grant 10110728. M Colman is supported by Medical Research Council Career Development Award (Grant Number MR/V010050/1).

We thank Eleonora Grandi, Stefano Morotti, Haibo Ni for useful discussions on how models derived from Shannon et al. operate. We thank Dirk Gillespie, Dezso Boda, Pavel Jungwirth, and Geir Halnes for their insights on how ionic driving force through open L-type calcium channels should or should not be modelled.

For the purpose of open access, the authors have applied a Creative Commons Attribution (CC-BY-NC) public copyright licence to any Author Accepted Manuscript version arising from this submission.

References

1. Natalia A Trayanova, Aurore Lyon, Julie Shade & Jordi Heijman. Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation. *Physiol Rev* **104**, 1265–1333 (2024).

2. Boyle, P. M. *et al*. Computationally guided personalized targeted ablation of persistent atrial fibrillation. *Nat Biomed Eng* **3**, 870 (2019).

3. Passini, E. *et al.* Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. *Front Physiol* **12**, 668 (2017).

4. Tomek, J. *et al.* Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block. *Elife* **8**, e48890 (2019).

5. Passini, E. *et al.* The virtual assay software for human in silico drug trials to augment drug cardiac testing. *J Comput Sci* **52**, 101202 (2021).

6. Credibility of Computational Models Program: Research on Computational Models and Simulation Associated with Medical Devices | FDA. https://www.fda.gov/medical-devices/medical-device-regulatory-science-research-programs-conducted-osel/credibility-computational-models-program-research-computational-models-and-simulation-associated.

7. Musuamba, F. T. *et al.* Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility. *CPT Pharmacometrics Syst Pharmacol* **10**, 804–825 (2021).

8. Corral-Acero, J. *et al.* The 'Digital Twin' to enable the vision of precision cardiology. *Eur Heart J* **41**, 4556–4564 (2020).

9. Varró, A. *et al.* Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior. *Physiol Rev* **101**, 1083–1176 (2021).

10. Medicines Agency, E. EMA Regulatory Science to 2025 Strategic reflection. (2025).

11. Shannon, T. R., Wang, F., Puglisi, J., Weber, C. & Bers, D. M. A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. *Biophys J* **87**, 3351–3371 (2004).

12. Grandi, E., Pasqualini, F. S. & Bers, D. M. A novel computational model of the human ventricular action potential and Ca transient. *J Mol Cell Cardiol* **48**, 112–121 (2010).

13. Morotti, S. *et al.* Quantitative cross-species translators of cardiac myocyte electrophysiology: Model training, experimental validation, and applications. *Sci Adv* **7**, 927 (2021).

14. Tusscher, K. H. W. J. ten & Panfilov, A. V. Alternans and spiral breakup in a human ventricular tissue model. *Am J Physiol Heart Circ Physiol* **291**, H1088–H1100 (2006).

15. Weiss, J. N., Garfinkel, A., Karagueuzian, H. S., Chen, P. S. & Qu, Z. Early afterdepolarizations and cardiac arrhythmias. *Heart Rhythm* **7**, 1891–1899 (2010).

16. Liu, M. B., De Lange, E., Garfinkel, A., Weiss, J. N. & Qu, Z. Delayed afterdepolarizations generate both triggers and a vulnerable substrate promoting reentry in cardiac tissue. *Heart rhythm : the official journal of the Heart Rhythm Society* **12**, 2115 (2015).

17. Edwards, J. N. & Blatter, L. A. Cardiac alternans and intracellular calcium cycling. *Clin Exp Pharmacol Physiol* **41**, 524–532 (2014).

18. Shattock, M. J. *et al.* Restitution slope is principally determined by steady-state action potential duration. *Cardiovasc Res* **113**, 817–828 (2017).

19. O'Hara, T., Virág, L., Varró, A. & Rudy, Y. Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation. *PLoS Comput Biol* **7**, e1002061 (2011).

20. Coppini, R. *et al.* Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. *Circulation* **127**, 575–584 (2013).

21. Margara, F. *et al.* In-silico human electro-mechanical ventricular modelling and simulation for drug-induced pro-arrhythmia and inotropic risk assessment. *Prog Biophys Mol Biol* **159**, (2021).

22. Land, S. *et al.* A model of cardiac contraction based on novel measurements of tension development in human cardiomyocytes. *J Mol Cell Cardiol* **106**, (2017).

23. Weiss, J. N. *et al.* 'Good enough solutions' and the genetics of complex diseases. *Circ Res* **111**, 493–504 (2012).

24. Heijman, J., Volders, P. G. A., Westra, R. L. & Rudy, Y. Local control of β-adrenergic stimulation: Effects on ventricular myocyte electrophysiology and Ca(2+)-transient. *J Mol Cell Cardiol* **50**, 863–871 (2011).

25. Linde, C. *et al.* Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. *Europace* **20**, 1565–1565ao (2018).

26. Holmes, M. *et al.* Sex-specific human electromechanical multiscale in-silico models for virtual therapy evaluation. *bioRxiv* 2025.03.14.643310 (2025) doi:10.1101/2025.03.14.643310.

27. Yang, P. C. & Clancy, C. E. In silico Prediction of Sex-Based Differences in Human Susceptibility to Cardiac Ventricular Tachyarrhythmias. *Front Physiol* **3**, (2012).

28. Peirlinck, M., Sahli Costabal, F. & Kuhl, E. Sex Differences in Drug-Induced Arrhythmogenesis. *Front Physiol* **12**, 708435 (2021).

29. Martinez-Navarro, H., Mincholé, A., Bueno-Orovio, A. & Rodriguez, B. High arrhythmic risk in antero-septal acute myocardial ischemia is explained by increased transmural reentry occurrence. *Scientific Reports 2019 9:1* **9**, 1–12 (2019).

30. Martinez-Navarro, H. *et al.* ECG analysis of ventricular fibrillation dynamics reflects ischaemic progression subject to variability in patient anatomy and electrode location. *Front Cardiovasc Med* **11**, 1408822 (2024).

31. Martinez-Navarro, H., Zhou, X., Bueno-Orovio, A. & Rodriguez, B. Electrophysiological and anatomical factors determine arrhythmic risk in acute myocardial ischaemia and its modulation by sodium current availability. *Interface Focus* **11**, 20190124 (2020).

32. Guo, D. *et al.* Electrophysiological properties of HBI-3000: A new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. *J Cardiovasc Pharmacol* **57**, 79–85 (2011).

33. Sims, C. *et al.* Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with drug-induced long QT type 2. *Circ Res* **102**, (2008).

34. Vandersickel, N., Van Nieuwenhuyse, E., Seemann, G. & Panfilov, A. V. Spatial Patterns of Excitation at Tissue and Whole Organ Level Due to Early Afterdepolarizations. *Front Physiol* **8**, 404 (2017).

35. Lehmann, M. H., Hardy, S., Archibald, D., Quart, B. & MacNeil, D. J. Sex difference in risk of torsade de pointes with d,l-sotalol. *Circulation* **94**, 2534–2541 (1996).

36. Papp, R. *et al.* Genomic upregulation of cardiac Cav1.2α and NCX1 by estrogen in women. *Biol Sex Differ* **8**, 1–11 (2017).

37. Qu, Z. *et al.* R-on-T and the initiation of reentry revisited: Integrating old and new concepts. *Heart Rhythm* **19**, 1369–1383 (2022).

38. Xie, L. H. & Weiss, J. N. Arrhythmogenic consequences of intracellular calcium waves. *Am J Physiol Heart Circ Physiol* **297**, 997–1002 (2009).

39. Hoeker, G. S., Katra, R. P., Wilson, L. D., Plummer, B. N. & Laurita, K. R. Spontaneous calcium release in tissue from the failing canine heart. *Am J Physiol Heart Circ Physiol* **297**, H1235 (2009).

40. Colman, M. A. *et al.* Multi-Scale Computational Modeling of Spatial Calcium Handling From Nanodomain to Whole-Heart: Overview and Perspectives. *Front Physiol* **13**, (2022).

41. Roshan, N. & Pandit, R. Multiscale studies of delayed afterdepolarizations I: A comparison of two biophysically realistic mathematical models for human ventricular myocytes. Preprint at https://arxiv.org/abs/2307.10134v1 (2023).

42. Voigt, N. *et al.* Enhanced sarcoplasmic reticulum Ca 2+ Leak and increased Na +-Ca 2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation* **125**, 2059–2070 (2012).

43. Domeier, T. L., Maxwell, J. T. & Blatter, L. A. β-Adrenergic stimulation increases the intra-sarcoplasmic reticulum Ca2+ threshold for Ca2+ wave generation. *J Physiol* **590**, 6093 (2012).

44. Colman, M. A. Arrhythmia mechanisms and spontaneous calcium release: Bi-directional coupling between re-entrant and focal excitation. *PLoS Comput Biol* **15**, e1007260 (2019).

45. Weiss, J. N. *et al.* From pulsus to pulseless: The saga of cardiac alternans. *Circ Res* **98**, 1244–1253 (2006).

46. Tanno, K. *et al.* Microvolt T-wave alternans as a predictor of ventricular tachyarrhythmias: a prospective study using atrial pacing. *Circulation* **109**, 1854–1858 (2004).

47. Pruvot, E. J., Katra, R. P., Rosenbaum, D. S. & Laurita, K. R. Role of Calcium Cycling Versus Restitution in the Mechanism of Repolarization Alternans. *Circ Res* **94**, 1083–1090 (2004).

48. Koller, M. L. *et al.* Altered dynamics of action potential restitution and alternans in humans with structural heart disease. *Circulation* **112**, 1542–1548 (2005).

49. Fukaya, H. *et al.* Arrhythmogenic cardiac alternans in heart failure is suppressed by late sodium current blockade by ranolazine. *Heart Rhythm* **16**, 281–289 (2019).

50. Wan, X. *et al.* New experimental evidence for mechanism of arrhythmogenic membrane potential alternans based on balance of electrogenic I(NCX)/I(Ca) currents. *Heart Rhythm* **9**, 1698–1705 (2012).

51. Wang, L. *et al.* Optical Mapping of Sarcoplasmic Reticulum Ca2+ in the Intact Heart: Ryanodine Receptor Refractoriness During Alternans and Fibrillation. *Circ Res* **114**, 1410 (2014).

52. Koller, M. L., Riccio, M. L. & Gilmour, R. F. Dynamic restitution of action potential duration during electrical alternans and ventricular fibrillation. *Am J Physiol* **275**, H1635–H1642 (1998).

53. Wang, L., Myles, R. C., Lee, I. J., Bers, D. M. & Ripplinger, C. M. Role of Reduced Sarco-Endoplasmic Reticulum Ca2+-ATPase Function on Sarcoplasmic Reticulum Ca2+ Alternans in the Intact Rabbit Heart. *Front Physiol* **12**, 656516 (2021).

54. Wan, X., Laurita, K. R., Pruvot, E. J. & Rosenbaum, D. S. Molecular correlates of repolarization alternans in cardiac myocytes. *J Mol Cell Cardiol* (2005) doi:10.1016/j.yjmcc.2005.06.004.

55. Tomek, J. *et al.* B-Adrenergic receptor stimulation and alternans in the border zone of a healed infarct: An ex vivo Study and Computational Investigation of Arrhythmogenesis. *Front Physiol* **29**, (2019).

56. Cutler, M. J., Wan, X., Laurita, K. R., Hajjar, R. J. & Rosenbaum, D. S. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. *Circ Arrhythm Electrophysiol* **2**, 686 (2009).

57. Child, N. *et al.* An activation-repolarization time metric to predict localized regions of high susceptibility to re-entry. *Heart Rhythm* **12**, 1644 (2015).

58. Taggart, P. *et al.* Effect of adrenergic stimulation on action potential duration restitution in humans. *Circulation* **107**, 285–289 (2003).

59. Nash, M. P. *et al.* Whole heart action potential duration restitution properties in cardiac patients: a combined clinical and modelling study. *Exp Physiol* **91**, 339–354 (2006).

60. Jing, L., Brownson, K. & Patwardhan, A. Role of slow delayed rectifying potassium current in dynamics of repolarization and electrical memory in swine ventricles. *J Physiol Sci* **64**, 185 (2014).

61. Tolkacheva, E. G., Anumonwo, J. M. B. & Jalife, J. Action Potential Duration Restitution Portraits of Mammalian Ventricular Myocytes: Role of Calcium Current. *Biophys J* **91**, 2735–2745 (2006).

62. Yamauchi, S. *et al.* Restitution Properties and Occurrence of Ventricular Arrhythmia in LQT2 Type of Long QT Syndrome. *J Cardiovasc Electrophysiol* **13**, 910–914 (2002).

63. Árpádffy-Lovas, T. *et al.* Electrical Restitution and Its Modifications by Antiarrhythmic Drugs in Undiseased Human Ventricular Muscle. *Front Pharmacol* **11**, 1 (2020).

64. Orini, M., Taggart, P., Srinivasan, N., Hayward, M. & Lambiase, P. D. Interactions between Activation and Repolarization Restitution Properties in the Intact Human Heart: In-Vivo Whole-Heart Data and Mathematical Description. *PLoS One* **11**, e0161765 (2016).

65. Pak, H. N. *et al.* Spatial Dispersion of Action Potential Duration Restitution Kinetics Is Associated with Induction of Ventricular Tachycardia/Fibrillation in Humans. *J Cardiovasc Electrophysiol* **15**, 1357–1363 (2004).

66. Mamoshina, P., Rodriguez, B. & Bueno-Orovio, A. Toward a broader view of mechanisms of drug cardiotoxicity. *Cell Rep Med* **2**, 100216 (2021).

67. crediblemeds.org. (2024).

68. Johannesen, L. *et al.* Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. *Clin Pharmacol Ther* **99**, 214–223 (2016).

69. Crotti, L. *et al.* Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes, Transgenic Rabbits, and Patients. *Circulation* **150**, (2024).

70. Tomek, J. *et al.* Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block. *Elife* **8**, e48890 (2019).

71. Lynge, T. H. *et al.* Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark. *Eur Heart J* **41**, 2699–2706 (2020).

72. Ashrafi, R. *et al.* Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. *Exp Physiol* **102**, 1424–1434 (2017).

73. Veglio, M. *et al.* Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. *J Intern Med* **251**, 317–324 (2002).

74. Ninkovic, V. M. *et al.* Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. *Acta Diabetol* **53**, 737–744 (2016).

75. Bertrand, A., Lewis, A., Camps, J., Grau, V. & Rodriguez, B. Multi-modal characterisation of early-stage, subclinical cardiac deterioration in patients with type 2 diabetes. *Cardiovasc Diabetol* **23**, 371 (2024).

76. Perkiömäki, J. *et al.* Heart Rate Turbulence and T-Wave Alternans in Patients with Coronary Artery Disease: The Influence of Diabetes. *Ann Noninvasive Electrocardiol* **20**, 481–487 (2015).

77. Bonapace, S. *et al.* Relationship Between Early Diastolic Dysfunction and Abnormal Microvolt T-Wave Alternans in Patients With Type 2 Diabetes. *Circ Cardiovasc Imaging* **4**, 408–414 (2011).

78. Casini, S. *et al.* Absence of Functional Nav1.8 Channels in Non-diseased Atrial and Ventricular Cardiomyocytes. *Cardiovasc Drugs Ther* **33**, 649–660 (2019).

79. Ahmad, S. *et al.* The functional consequences of sodium channel NaV1.8 in human left ventricular hypertrophy. *ESC Heart Fail* **6**, 154 (2019).

80. Dybkova, N. *et al.* CaMKII delta interaction with neuronal sodium channel Nav1.8 contributes to arrhythmogenic triggers in failing human and mouse cardiomyocytes. *Eur Heart J* **41**, (2020).

81. Bengel, P. *et al.* Contribution of the neuronal sodium channel NaV1.8 to sodium- and calcium-dependent cellular proarrhythmia. *J Mol Cell Cardiol* **144**, 35–46 (2020).

82. Coleman, J. A. *et al.* Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy. *Front Pharmacol* **15**, 1379236 (2024).

83. Rajamani, S., Shryock, J. C. & Belardinelli, L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. *Channels (Austin)* **2**, 449–460 (2008).

84. Ernst, P., Bidwell, P. A., Dora, M., Thomas, D. D. & Kamdar, F. Cardiac calcium regulation in human induced pluripotent stem cell cardiomyocytes: Implications for disease modeling and maturation. *Front Cell Dev Biol* **10**, 986107 (2023).

85. Trovato, C. *et al.* In silico predictions of drug-induced changes in human cardiac contractility agree with experimental recordings. *Front Pharmacol* **16**, 1500668.

86. DeFilippis, E. M. & Van Spall, H. G. C. Is it Time for Sex-Specific Guidelines for Cardiovascular Disease? *J Am Coll Cardiol* **78**, 189–192 (2021).

87. Oravecz, K. *et al.* Inotropic effect of NCX inhibition depends on the relative activity of the reverse NCX assessed by a novel inhibitor ORM-10962 on canine ventricular myocytes. *Eur J Pharmacol* **818**, 278–286 (2018).

88. Szlovák, J. *et al.* Blockade of sodium-calcium exchanger via ORM-10962 attenuates cardiac alternans. *J Mol Cell Cardiol* (2021) doi:10.1016/j.yjmcc.2020.12.015.

89. Shivkumar, K. *et al.* Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. *J Physiol* **594**, 3911–3954 (2016).

90. Meier, S., Grundland, A., Dobrev, D., Volders, P. G. A. & Heijman, J. In silico analysis of the dynamic regulation of cardiac electrophysiology by Kv 11.1 ion-channel trafficking. *J Physiol* **601**, 2711–2731 (2023).

91. Cortassa, S., Juhaszova, M., Aon, M. A., Zorov, D. B. & Sollott, S. J. Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin? *J Mol Cell Cardiol* **151**, 113–125 (2021).

92. Ngo, K., Yang, P.-C., Yarov-Yarovoy, V., Clancy, C. E. & Vorobyov, I. Harnessing AlphaFold to reveal hERG channel conformational state secrets. *Elife* **13**, (2024).